beta-peptide immunization: a possible new treatment for Alzheimer disease.
暂无分享,去创建一个
[1] I. Lieberburg,et al. Cellular mechanisms of beta-amyloid production and secretion. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[2] R. Motter,et al. Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse , 1999, Nature.
[3] L. Thal,et al. Neuropsychological function and apolipoprotein E genotype in the preclinical detection of Alzheimer's disease. , 1999, Psychology and aging.
[4] C. Lippa,et al. Aβ−42 deposition precedes other changes in PS-1 Alzheimer's disease , 1998, The Lancet.
[5] D. Price,et al. Altered metabolism of familial Alzheimer's disease-linked amyloid precursor protein variants in yeast artificial chromosome transgenic mice. , 1997, Human molecular genetics.
[6] J. Trojanowski,et al. Strategies for Improving the Postmortem Neuropathological Diagnosis of Alzheimer’s Disease , 1997, Neurobiology of Aging.
[7] Allan I. Levey,et al. Familial Alzheimer's Disease–Linked Presenilin 1 Variants Elevate Aβ1–42/1–40 Ratio In Vitro and In Vivo , 1996, Neuron.
[8] R. Broadwell,et al. Transcytosis of Protein through the Mammalian Cerebral Epithelium and Endothelium III. Receptor-Mediated Transcytosis through the Blood–Brain Barrier of Blood-Borne Transferrin and Antibody against the Transferrin Receptor , 1996, Experimental Neurology.
[9] S. Younkin,et al. Correlative Memory Deficits, Aβ Elevation, and Amyloid Plaques in Transgenic Mice , 1996, Science.
[10] G. Schellenberg,et al. Secreted amyloid β–protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease , 1996, Nature Medicine.
[11] L. Mucke,et al. Neurotrophic and Neuroprotective Effects of hAPP in Transgenic Mice a , 1996, Annals of the New York Academy of Sciences.
[12] R. Wolfert,et al. Reduction of β‐amyloid peptide42 in the cerebrospinal fluid of patients with Alzheimer's disease , 1995 .
[13] J. Higaki,et al. Inhibition of β-amyloid formation identifies proteolytic precursors and subcellular site of catabolism , 1995, Neuron.
[14] L. Mucke,et al. Alzheimer-type neuropathology in transgenic mice overexpressing V717F β-amyloid precursor protein , 1995, Nature.
[15] U. Wurster,et al. Passage of intravenous immunoglobulin and interaction with the CNS. , 1994, Journal of neurology, neurosurgery, and psychiatry.
[16] D. Selkoe,et al. Alzheimer's Disease: A Central Role for Amyloid , 1994, Journal of neuropathology and experimental neurology.
[17] S. Younkin,et al. An increased percentage of long amyloid beta protein secreted by familial amyloid beta protein precursor (beta APP717) mutants. , 1994, Science.
[18] M. Sofroniew,et al. Serum Proteins Bypass the Blood-Brain Fluid Barriers for Extracellular Entry to the Central Nervous System , 1993, Experimental Neurology.
[19] D. Selkoe,et al. Mutation of the β-amyloid precursor protein in familial Alzheimer's disease increases β-protein production , 1992, Nature.
[20] E. Thompson,et al. Laboratory Investigation of Cerebrospinal Fluid Proteins , 1990, Annals of clinical biochemistry.
[21] M. Folstein,et al. Clinical diagnosis of Alzheimer's disease , 1984, Neurology.
[22] D. Selkoe,et al. A Substrate-Based Difluoro Ketone Selectively Inhibits Alzheimer's γ-Secretase Activity , 1998 .
[23] Weiming Xia,et al. Mutant presenilins of Alzheimer's disease increase production of 42-residue amyloid β-protein in both transfected cells and transgenic mice , 1997, Nature Medicine.